Efficacy and Safety of the Topotecan–Cyclophosphamide Regimen in Adult Metastatic Ewing Sarcoma: A Large, Multicenter, Real-World Study
Cancers, cilt.17, sa.3, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 17 Sayı: 3
- Basım Tarihi: 2025
- Doi Numarası: 10.3390/cancers17030550
- Dergi Adı: Cancers
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, EMBASE
- Anahtar Kelimeler: Ewing sarcoma, second-line chemotherapy, topotecan, cyclophosphamide, efficacy, safety, metastasis
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Ewing sarcoma is a malignant tumor that frequently occurs in adolescents and young adults, primarily originating from bone and rarely from soft tissue. Approximately 25% of patients present with metastatic disease at the time of diagnosis. Ewing sarcoma is considered a systemic disease, with the standard treatment consisting of a multimodal approach that combines surgery, radiotherapy, and chemotherapy. However, the optimal second-line or subsequent-line treatment for patients who progress after first-line chemotherapy remains unclear. Treatment options include high-dose ifosfamide, gemcitabine–docetaxel, topotecan–cyclophosphamide, and vincristine–irinotecan–temozolomide. The aim of this study was to evaluate the efficacy and safety of the topotecan–cyclophosphamide regimen in adult patients with metastatic Ewing sarcoma. The topotecan–cyclophosphamide regimen appears to be a viable treatment option regarding efficacy and safety for patients who progress after first-line therapy. However, further research is needed to better define its role in treatment.